The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing Escherichia coli bacteraemia

BMC Infectious Diseases

Jiun-Ling Wang¹  Chih-Hsin Hung²  Hsi-Hsun Lin¹  Chung-Hsu Lai¹  Ming-Fang Cheng³  Yi-Hui Wu¹ 

[1] Department of Internal Medicine, E-Da Hospital, College of Medicine, I-Shou University, Kaohsiung, Taiwan;Department of Chemical Engineering, Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan

关键词: Mortality;    ST (sequence type) 131;    Fluoroquinolone resistant;    Community onset;    Bacteraemia;    E. coli;   

Others  :  1125393
DOI  :  10.1186/s12879-014-0579-z

 received in 2014-05-31, accepted in 2014-10-22,  发布年份 2014

【 摘 要 】

Background

To compare the epidemiological and clinical features and outcome in clonal group O25b/ST131 and non-clonal group O25b/ST131 in adult patients with non-extended-spectrum B-lactamase (ESBL)-producing Escherichia coli (E. coli) bacteraemia.

Methods

We collected 371 consecutive isolates with community-onset non-ESBL producing E. coli bloodstream infection in 2010 in a 1200-bed hospital in Taiwan. Twenty adult patients with clonal group O25b/ST131 and 40 patients with non-clonal group O25b/ST131 were compared.

Result

Clonal group O25b/ST131 accounted for 5.9% of total isolates. The underlying disease and healthcare-associated risk factors were similar in the case and control groups. Patients with the clonal group O25b/ST131 were less likely to have intra-abdominal infection (0% vs. 22.5%; p < 0.05) than patients from the control group. The Day 30 mortality rate was similar in the case and control groups (15% vs. 12.5%).

Conclusions

Clonal group O25b/ST131 was found in both multidrug-resistant and susceptible E. coli strains, causing community-onset bloodstream infection. Although O25b/ST131 does not lead to a higher mortality than other isolates, choosing an appropriate antimicrobials in the empirical therapy of community-onset E. coli bacteraemia has become more challenging.

【 授权许可】

   
2014 Wu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Caniça MM, Park YJ, Lavigne JP, Pitout J, Johnson JR: Intercontinental emergence of Escherichia coli clone O25:H4–ST131 producing CTX-M-15. J Antimicrob Chemother 2008, 61:273-281.
• [2]Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppé E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E: Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009, 64:274-277.
• [3]Peirano G, Pitout JD: Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010, 35:316-321.
• [4]Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD, Kuskowski MA: Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerg Infect Dis 2012, 18:598-607.
• [5]Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M: Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010, 51:286-294.
• [6]Yokota S, Sato T, Okubo T, Ohkoshi Y, Okabayashi T, Kuwahara O, Tamura Y, Fujii N: Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan. Chemotherapy 2012, 58:52-59.
• [7]Uchida Y, Mochimaru T, Morokuma Y, Kiyosuke M, Fujise M, Eto F, Eriguchi Y, Nagasaki Y, Shimono N, Kang D: Clonal spread in Eastern Asia of ciprofloxacin-resistant Escherichia coli serogroup O25 strains, and associated virulence factors. Int J Antimicrob Agents 2010, 35:444-450.
• [8]Lee MY, Choi HJ, Choi JY, Song M, Song Y, Kim SW, Chang HH, Jung SI, Kim YS, Ki HK, Son JS, Kwon KT, Heo ST, Yeom JS, Shin SY, Chung DR, Peck KR, Song JH, Ko KS: Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea. J Infect 2010, 60:146-153.
• [9]Wu YH, Chen PL, Hung YP, Ko WC: Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.J Microbiol Immunol Infect 2012, Oct 11(E-Pub).
• [10]Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, Shih YC, Lin HH, Wang JL: Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 2012, 56:618-622.
• [11]Adams-Sapper S, Diep BA, Perdreau-Remington F, Riley LW: Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 2013, 57:490-497.
• [12]Horner C, Fawley W, Morris K, Parnell P, Denton M, Wilcox M: Escherichia coli bacteraemia: 2 years of prospective regional surveillance (2010-12). J Antimicrob Chemother 2014, 69:91-100.
• [13]López-Cerero L, Navarro MD, Bellido M, Martín-Peña A, Viñas L, Cisneros JM, Gómez-Langley SL, Sánchez-Monteseirín H, Morales I, Pascual A, Rodríguez-Baño J: Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014, 69:809-814.
• [14]Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E: Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012, 80:1554-1562.
• [15]Vimont S, Boyd A, Bleibtreu A, Bens M, Goujon JM, Garry L, Clermont O, Denamur E, Arlet G, Vandewalle A: The CTX-M-15-producing Escherichia coli clone O25b: H4–ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012, 7:e46547.
• [16]Tchesnokova V, Billig M, Chattopadhyay S, Linardopoulou E, Aprikian P, Roberts PL, Skrivankova V, Johnston B, Gileva A, Igusheva I, Toland A, Riddell K, Rogers P, Qin X, Butler-Wu S, Cookson BT, Fang FC, Kahl B, Price LB, Weissman SJ, Limaye A, Scholes D, Johnson JR, Sokurenko EV: Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol 2013, 51:2991-2999.
• [17]Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, Huang CC, Liu CE, Ko WC, Wang JH, Tang HJ, Yu KW, Chen YS, Chuang YC, Xu Y, Ni Y, Chen YH, Hsueh PR: Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 resultsfrom the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int JAntimicrob Agents 2012, 40(Suppl):S37-S43.
• [18]Lee SS, Kim Y, Chung DR: Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect 2011, 62:159-164.
• [19]Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, Rozwadowski J, Mehler PS, Price CS: Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008, 121:876-884.
• [20]van der Starre WE, van Nieuwkoop C, Paltansing S, van't Wout JW, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, Blom JW, van Dissel JT: Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011, 6:6650-6656.